Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men
Progress in Cardiovascular Diseases · 2024
DOI: 10.1016/j.pcad.2024.02.015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2024. Verfasst von Srikanth Krishnan und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Lundquist Institute at Harbor-UCLA, 1124 W Carson St, Torrance, CA 90502. Electronic address: Srikanth.krishnan@lundquist.org. Hauptthemen laut MEDLINE: Testosterone, Cardiovascular Diseases, Hypogonadism, Heart Disease Risk Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
The debate over the cardiovascular (CV) implications of testosterone therapy (TT) have resulted in diverging safety recommendations and clinical guidelines worldwide. This narrative review synthesizes and critically evaluates long-term studies examining the effects of TT within the context of aging, obesity, and endogenous sex hormones on CV disease (CVD) risk to support informed clinical decision-making. Observational studies have variably linked low endogenous testosterone with increased CVD risk, while randomized controlled trials (RCTs) demonstrate that TT yields cardiometabolic benefits without increasing short-term CV risk. The TRAVERSE trial, as the first RCT powered to assess CVD events, did not show increased major adverse cardiac events (MACE) incidence; however, its limitations - specifically the maintenance of testosterone at low-normal levels, a high participant discontinuation rate, and short follow-up - warrant a careful interpretation of its results. Furthermore, findings from the TTrials cardiovascular sub-study, which showed an increase in non-calcified plaque, indicate the need for ongoing research into the long-term CV impact of TT. The decision to initiate TT should consider the current evidence gaps, particularly for older men with known CVD. The CV effects of maintaining physiological testosterone levels through exogenous means remain to be fully explored. Until more definitive evidence is available, clinical practice should prioritize individualized care and informed discussions on the potential CV implications of TT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Lundquist Institute at Harbor-UCLA, 1124 W Carson St, Torrance, CA 90502. Electronic address: Srikanth.krishnan@lundquist.org.
- The Lundquist Institute at Harbor-UCLA, 1124 W Carson St, Torrance, CA 90502.
- The Lundquist Institute at Harbor-UCLA, 1124 W Carson St, Torrance, CA 90502; David Geffen School of Medicine at University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095.
- The Lundquist Institute at Harbor-UCLA, 1124 W Carson St, Torrance, CA 90502. Electronic address: mbudoff@lundquist.org.
Zitieren
APA
Krishnan, S., Aldana-Bitar, J., Golub, I., Ichikawa, K., Shabir, A., Bagheri, M., Hamidi, H., Benzing, T., Kianoush, S., & Budoff, M. J. (2024). Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.02.015
Vancouver
Krishnan S, Aldana-Bitar J, Golub I, Ichikawa K, Shabir A, Bagheri M, et al. Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men. Progress in Cardiovascular Diseases. 2024. doi:10.1016/j.pcad.2024.02.015
BibTeX
@article{Krishnan2024,
author = {Krishnan, Srikanth and Aldana-Bitar, Jairo and Golub, Ilana and Ichikawa, Keishi and Shabir, Ayesha and Bagheri, Marziyeh and Hamidi, Hossein and Benzing, Travis and Kianoush, Sina and Budoff, Matthew J},
title = {Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men},
journal = {Progress in Cardiovascular Diseases},
year = {2024},
doi = {10.1016/j.pcad.2024.02.015}
}
EUVIMED